Silence Therapeutics advances next RNAi medicine
Lipoprotein(a) targeting, an exciting approach to address cardiovascular disease
December 19, 2018
LONDON, Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces the addition of a new siRNA (short interfering RNA) asset to its pre-clinical pipeline for the potential treatment of cardiovascular disease.
The product candidate, SLN360, silences apolipoprotein (a), a component of lipoprotein(a) (“LP(a)”), which is a highly validated target based on extensive human genetic data. Elevated LP(a) levels have been associated with increased risk of cardiovascular disease, independent of additional risk factors.
Data generated in non-human primates show that Silence’s proprietary GalNAc-siRNA candidate SLN360 yields potent and durable serum LP(a) knockdown for over six weeks following a low single dose, with higher doses resulting in sustained knockdown (>90%) for at least two months with no trend back to baseline levels observed. These performance data, together with the subcutaneous administration route and safety profile of our molecules, support an infrequent and patient-friendly dosing regimen. The IND/CTA for SLN360 is anticipated to be filed in the second half of 2020.
David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:
“We are excited to add SLN360, our new LP(a) targeting siRNA medicine, to our pipeline of wholly owned assets aimed at addressing areas of significant unmet need. High LP(a) levels in humans increase the probability of significant cardiovascular disease and lowering these levels is associated with reducing cardiovascular risks and disease. Our data suggest that SLN360 significantly reduces serum LP(a) in non-human primates for up to two months and ultimately will use patient convenient sub-cutaneous dosing. We are poised to advance SLN360 towards the clinic as a new medicine for patients with significant cardiovascular risk. “
Enquiries:
| Silence Therapeutics plc Dr David Horn Solomon, Chief Executive Officer David Ellam, Chief Financial Officer | Tel: +44 (0)20 3457 6900 |
| Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson | Tel: +44 (0)20 7418 8900 |
| European IR Consilium Strategic Communications Mary-Jane Elliott / Angela Gray silencetherapeutics@consilium-comms.com | Tel: +44 (0) 20 3709 5700 |
| US IR Westwicke Partners Peter Vozzo peter.vozzo@westwicke.com | Tel: +1 (443) 213-0505 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural
mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and
delivery systems are designed to improve the stability of our molecules and enhance effective delivery
to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
For more information, please visit: https://www.silence-therapeutics.com/